Eltromag 25mg Tablet

Eltromag 25mg Tablet is prescribed by the doctor to treat low platelet counts in specific blood-related conditions. It is mainly given in combination with other medicines to treat a particular condition or increase effectiveness. Elromo 50mg Tablet contains Eltrombopag that promotes the proliferation and differentiation of megakaryocytes, leading to increased platelet formation and reduced bleeding risk in conditions like chronic ITP, hepatitis C-related thrombocytopenia, or severe aplastic anemia. Take it exactly as prescribed by the doctor.

• Chronic idiopathic thrombocytopenia
• Severe Aplastic Anemia
• Low platelet count due to ITP or HCV infection

Eltromag 25mg Tablet can cause multiple side effects, most of which are mild to moderate and often temporary. Patients are advised to inform their healthcare provider immediately if symptoms stays for prolonged period of time.

• Headache
• Nausea
• Tiredness
• Diarrhea
• Insomnia
• Dizziness
• Loss of Appetite
• Rashes
• Muscle Pain
• Fever
• Chills
• Allergic Reaction
• Liver Problem
• Blood Clots
• Allergic Reaction

• The usual dose of Eltromag 25mg Tablet is one tablet daily. It should be taken on an empty stomach, at the same time each day for consistent blood levels. Consult your doctor for individual dosage as it may vary person to person based on its stage and overall health.
• Tablet is taken orally with the help of water. Avoid breaking, chewing, biting and crushing of tablet to maintain the medication efficacy.
  

• Eltromag 25mg Tablet contains Eltrombopag, Eltrombopag binds to and activates the trans-membrane domain of the TPO receptor (c-Mpl) on megakaryocyte progenitors in the bone marrow, triggering signaling pathways.
• This promotes the proliferation and differentiation of megakaryocytes, leading to increased platelet formation and reduced bleeding risk in conditions like chronic ITP, hepatitis C-related thrombocytopenia, or severe aplastic anemia.

• Elgebaly, A. S., Ashal, G. E., Elfil, M., & Menshawy, A. (2017). Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia: meta-analysis of randomized controlled trials. Clinical and Applied Thrombosis/Hemostasis, 23(8), 928-937. https://pubmed.ncbi.nlm.nih.gov/27572890/
• Wong, R. S., Saleh, M. N., Khelif, A., Salama, A., Portella, M. S. O., Burgess, P., & Bussel, J. B. (2017). Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood, The Journal of the American Society of Hematology, 130(23), 2527-2536. https://pubmed.ncbi.nlm.nih.gov/29042367/
• Bussel, J. B., Cheng, G., Saleh, M. N., Psaila, B., Kovaleva, L., Meddeb, B., ... & Jenkins, J. M. (2007). Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine, 357(22), 2237-2247. https://pubmed.ncbi.nlm.nih.gov/18046028/
• Saleh, M. N., Bussel, J. B., Cheng, G., Meyer, O., Bailey, C. K., Arning, M., & Brainsky, A. (2013). Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood, The Journal of the American Society of Hematology, 121(3), 537-545. https://pubmed.ncbi.nlm.nih.gov/23169778/
• Cheng, G., Saleh, M. N., Marcher, C., Vasey, S., Mayer, B., Aivado, M., ... & Bussel, J. B. (2011). Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. The Lancet, 377(9763), 393-402. https://pubmed.ncbi.nlm.nih.gov/20739054/
• Bussel, J. B., de Miguel, P. G., Despotovic, J. M., Grainger, J. D., Sevilla, J., Blanchette, V. S., ... & Bakshi, K. K. (2015). Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. The Lancet Haematology, 2(8), e315-e325. https://pubmed.ncbi.nlm.nih.gov/26688484/